ライフサイエンスコーパス: P for trend

1 ed by 0.07 every 2 years (95% CI, 0.04-0.10; p for trend 0.002).

2 R, 1.45; 95% confidence interval, 1.03-2.04; P for trend 0.02).

3 west quartile, RRadj 0.49, 95% CI 0.23-1.05, P for trend 0.024).

4 isit rate remained stable from 1994 to 2009 (p for trend 0.42).

5 0.86 (95% confidence interval: 0.79 to 0.93; p for trend = 0.0002) and 0.80 (95% confidence interval:

6 diseases was negatively associated with NHL (P for trend = 0.0003).

7 in 2002 to 27.4/100,000 (26.9-27.9) in 2009 (P for trend = 0.0008).

8 testosterone compared to those with no nevi (p for trend = 0.001 for both).

9 -8 hours/day, HR = 0.63, 95% CI: 0.48, 0.83; P for trend = 0.001).

10 rth increased with the duration of exposure (P for trend = 0.0014).

11 ease mortality (HR, 0.70 [CI, 0.55 to 0.90]; P for trend = 0.002) and a positive association with ova

12 ean diet was related to 46% (CI, 17% to 83%; P for trend = 0.002) greater odds of healthy aging.

13 ease, and stroke were 1.32 (CI,1.09 to 1.59; P for trend = 0.002), 1.30 (CI, 1.04 to 1.62; P for tren

14 elevated risk of rosacea among past smokers (P for trend = 0.003) and with a decreased risk of rosace

15 .15 (95% CI: 1.06, 1.24) for poultry intake (P for trend = 0.004), and 1.07 (95% CI: 0.99, 1.16) for

16 s the respective baseline SBP strata listed (p for trend = 0.004).

17 atios of 0.83 for EPA (95% CI, 0.71 to 0.98; P for trend = 0.005), 0.77 for DPA (CI, 0.66 to 0.90; P

18 nd = 0.008), 0.80 for DHA (CI, 0.67 to 0.94; P for trend = 0.006), and 0.73 for total omega3-PUFAs (C

19 for trend = 0.002), 1.30 (CI, 1.04 to 1.62; P for trend = 0.006), and 1.47 (CI, 0.97 to 2.21; P for

20 remained associated with Alzheimer disease (p for trend = 0.007) and all dementia (p for trend = 0.0

21 nd = 0.005), 0.77 for DPA (CI, 0.66 to 0.90; P for trend = 0.008), 0.80 for DHA (CI, 0.67 to 0.94; P

22 ial infarction (1.39 [95% CI: 1.02 to 1.88]; p for trend = 0.008), and stroke (1.60 [95% CI: 1.22 to

23 of odds of cataract or cataract extraction, (P for trend = 0.008).

24 eme fetuin-A quintiles was 1.81 (1.07-3.06) (P for trend = 0.009).

25 < 0.001; women: HR, 0.93 [CI, 0.87 to 0.98]; P for trend = 0.009).

26 mong NHW women (OR = 0.49, 95% CI 0.29-0.81, p for trend = 0.01) and invasive breast cancer (OR = 0.6

27 . quartile 1, OR = 0.49, 95% CI: 0.31, 0.78; P for trend = 0.01) were inversely associated with ovari

28 an Americans (HR = 2.21, 95% CI: 1.21, 4.03; P for trend = 0.01), whereas no associations were found

29 1-year mortality in a dose-dependent manner (p for trend = 0.01).

30 spital costs also declined over this period (p for trend = 0.011).

31 vaccination dosage and HBsAg-positive rate (P for trend = 0.011).

32 genic shock, decreasing from 51.6% to 43.1% (p for trend = 0.012).

33 viral hepatitis-related cirrhosis mortality (P for trend = 0.014).

34 ncer mortality (HR, 1.31 [CI, 1.07 to 1.61]; P for trend = 0.015).

35 2, 95% confidence interval (CI): 0.86, 0.98, P for trend = 0.01; and HR = 0.93, 95% CI: 0.88, 0.99, P

36 1, 95% confidence interval (CI): 0.52, 0.97; P for trend = 0.01; occupational sitting hours of <2 vs.

37 = 1.11, 95% confidence interval: 1.01, 1.23; P for trend = 0.02) and several subclasses were positive

38 ation per night and weight gain in both men (P for trend = 0.02) and women (P for trend < 0.001).

39 d 1.30 (95% confidence interval: 1.00, 1.69; P for trend = 0.02) for adipose tissue LI in the multiva

40 ve serology for hepatitis B surface antigen (P for trend = 0.02).

41 ted hazard ratio = 1.13, 95% CI: 1.01, 1.25; P for trend = 0.02).

42 tertiles of arsenic exposure, respectively (P for trend = 0.02).

43 minutes/day, HR = 0.59, 95% CI: 0.39, 0.90; P for trend = 0.02).

44 anic women (OR = 0.71, 95% CI 0.47-1.06, and P for trend = 0.02).

45 children of mothers with a basic education (P for trend = 0.02).

46 th those with a high school diploma or less (P for trend = 0.02); women with family annual incomes of

47 Mortality rates declined over this period (p for trend = 0.027) from 41.1% in 2004 to 2007 to 33.4%

48 . quartile 1, OR = 0.57, 95% CI: 0.36, 0.92; P for trend = 0.03) and AHEI-2010 (quartile 4 vs. quarti

49 ) for IGFBP-3, and 0.77 (95% CI: 0.57, 1.03; P for trend = 0.03) for IGF-1:IGFBP-3 ratio.

50 = 0.56, 95% confidence interval: 0.35, 0.90, P for trend = 0.03) over an average follow-up of 5.4 yea

51 f 1.21 (95% confidence interval: 1.02, 1.44; P for trend = 0.03).

52 nterval: 1.00, 3.53) for glycemic load (both P for trend = 0.03).

53 ted hazard ratio = 1.14, 95% CI: 1.02, 1.28; P for trend = 0.03).

54 trend = 0.006), and 1.47 (CI, 0.97 to 2.21; P for trend = 0.032).These associations varied by study

55 4 (95% confidence interval (CI): 0.44, 0.92; P for trend = 0.04) compared with women in the lowest qu

56 a relative risk of 1.46 (95% CI: 0.99, 2.15; P for trend = 0.04) compared with women in the lowest qu

57 = 0.31) for IGF-1, 1.33 (95% CI: 1.00, 1.76; P for trend = 0.04) for IGFBP-3, and 0.77 (95% CI: 0.57,

58 (P for trend = 0.05) and proanthocyanidins (P for trend = 0.04) with high-grade prostate cancer, but

59 R for 4th quartile = 0.83, 95% CI 0.66-1.03, p for trend = 0.04), primarily among Hispanic women (OR

60 hood exposure to microbes during early life (P for trend = 0.04).

61 ease (p for trend = 0.007) and all dementia (p for trend = 0.04).

62 ; HR = 1.27) to the distal colon (HR = 1.04; P for trend = 0.040).

63 evalence of cataract or cataract extraction (P for trend = 0.047).

64 e number of smokers in the house as a child (P for trend = 0.05) and exposure to 6 or more hours per

65 inverse trends with higher total flavonoids (P for trend = 0.05) and proanthocyanidins (P for trend =

66 e, relative risk = 0.69, 95% CI: 0.46, 1.02; P for trend = 0.05).

67 6, 95% confidence interval (CI): 0.45, 0.98; P for trend = 0.05).

68 d = 0.01; and HR = 0.93, 95% CI: 0.88, 0.99, P for trend = 0.05, respectively).

69 d with those with incomes less than $10,000 (P for trend = 0.055).

70 breast cancer (OR = 0.67, 95% CI 0.46-0.99, p for trend = 0.06), among NHW women (OR = 0.49, 95% CI

71 minutes/day, HR = 0.69, 95% CI: 0.50, 0.96; P for trend = 0.06), and rectal cancer (>90 vs. </=30 mi

72 st cancer also (OR = 0.73, 95% CI 0.53-1.00, p for trend = 0.06), particularly for the highest quarti

73 r (Odds Ratio (OR) = 0.50, 95% CI 0.25-1.00, p for trend = 0.07).

74 d with increasing duration of breastfeeding (P for trend = 0.08).

75 = 0.64, 95% confidence interval: 0.35, 1.17; P for trend = 0.09), especially for adenocarcinomas, but

76 % CI: 0.99, 1.16) for fish/shellfish intake (P for trend = 0.12).

77 eDi was not associated with phenoconversion (P for trend = 0.14 for tertile of MeDi, and P = .22 for

78 = 0.80, 95% confidence interval: 0.56, 1.14; P for trend = 0.20) or as a log-transformed continuous v

79 ult exposure (HR = 2.15, 95% CI: 1.23, 3.73; P for trend = 0.23), and was marginally significantly hi

80 1 (95% confidence interval (CI): 0.68, 1.23; P for trend = 0.31) for IGF-1, 1.33 (95% CI: 1.00, 1.76;

81 = 1.01, 95% confidence interval: 0.97, 1.05; P for trend = 0.35).

82 uintiles was attenuated to 1.09 (0.56-2.10) (P for trend = 0.42).

83 w [Q1] 25(OH)D = 0.96; 95% CI: 0.61 to 1.50; P for trend = 0.50).

84 = 0.62, 95% confidence interval: 0.29, 1.30; P for trend = 0.56).

85 men (from 2% to 1.8%, relative change 8.6%; p for trend = 0.60).

86 5% confidence interval (95% CI): 0.77, 1.17; P for trend = 0.63) compared with those who never did sh

87 , -4.3, -4.7, and -10.6 mm Hg, respectively (p for trend = 0.66).

88 trend < 0.001) but not women (7.6% to 7.5%; P for trend = 0.69).

89 information (HR = 1.40, 95% CI: 1.00, 1.97; P for trend = 0.74).

90 id not exhibit a significant decline (-8.1%, p-for-trend = 0.18).

91 nd black women but not for black men (-9.5%, p-for-trend = 0.43).

92 or fatal CHD were maintained but attenuated (P for trend =0.02), whereas the significant associations

93 ion in DNT was particularly marked in China (P for trend, 0.001), but was not significant across the

94 nt across the other participating countries (P for trend, 0.065).

95 sociated with the risk of colorectal cancer (p for trend, 0.45).

96 2; 95% confidence interval [CI]: 1.49-10.27; P for trend: 0.011) and multivariate-adjusted analyses (

97 usted analyses (HR, 2.68; 95% CI: 1.02-7.03; P for trend: 0.072).

98 A genotype had the highest incidence of IFG (P for trend=0.0003).

99 ratio of 0.94, P=0.808, with SBP>136 mm Hg (P for trend=0.001).

100 7 to -71]) versus normal glucose metabolism (P for trend=0.001).

101 to -0.25]) versus normal glucose metabolism (P for trend=0.001).

102 r: 1.04; 95% confidence interval, 1.01-1.08; P for trend=0.006).

103 est quartile was 0.53 (95% CI 0.33 to 0.84) (P for trend=0.006).

104 etter neurological outcomes among survivors (P for trend=0.01).

105 >/=once/week, HR=1.17 (95% CI: 1.02, 1.34)] (p for trend=0.01).

106 for trend<0.001), and in-hospital survival (P for trend=0.015).

107 for trend<0.001) and 2-hour glucose levels (P for trend=0.015).

108 eased significantly (N=6133, 16.2% to 19.7%; P for trend=0.021), although solely in patients presenti

109 acid was inversely associated with PD risk (P for trend=0.033).

110 ction in death [OR, 0.51; 95% CI, 0.49-0.67; P for trend=0.03] and major adverse events [OR, 0.75; 95

111 eased with increasing duration of lactation (P for trend=0.04).

112 adverse events [OR, 0.75; 95% CI, 0.66-0.84; P for trend=0.05] comparing years 2010 versus 2001).

113 o, 0.68; 95% confidence interval, 0.34-1.37; P for trend=0.13).

114 bility among survivors over time (unadjusted P for trend=0.32), suggesting an overall increase in the

115 f the GRS relating to 0.001 smaller CCA IMT, p for trend=0.930).

116 prescriptions: HR = 2.06, 95% CI, 0.82-5.16; P for trend = .002).

117 (hazard ratio [HR] 0.48; 95% CI, 0.28-0.83; P for trend=.003) and 30% reduced risk of all-cause deat

118 of hsCRP level was 1.78 (95% CI, 0.98-3.25; P for trend = .004), whereas for ICAM-1 level, the RR co

119 tality risk (HR, 0.69; 95% CI, 0.49 to 0.98; P for trend = .006), independent of prediagnosis activit

120 0.5] days in 2001 vs 7.6 [0.6] days in 2012, P for trend = .009), but in-patient mortality remained u

121 % CI, 1.11-1.73) for 6 years or more of use (P for trend = .009).

122 <25 vs >/=35: HR, 1.33 [95% CI, 0.90-1.97]; P for trend = .01) and African American men, although th

123 bottom quintile of 1.83 (95% CI, 0.94-3.55; P for trend = .01).

124 ay was 0.82 for all POAG (95% CI, 0.69-0.97; P for trend = .02) and 0.52 for POAG with paracentral VF

125 ovement among black patients on an absolute (P for trend = .02) and relative scale (P for interaction

126 <25 vs >/=35: HR, 0.80 [95% CI, 0.58-1.09]; P for trend = .02) but positively associated with risk w

127 erved over time, favoring time-based events (P for trend = .02).

128 ately 240 mg/d) was 0.79 (95% CI, 0.66-0.93; P for trend = .02).

129 <25 vs >/=35: HR, 1.81 [95% CI, 0.79-4.11]; P for trend = .02).

130 e mortality (HR, 0.80; 95% CI, 0.68 to 0.95; P for trend = .021).

131 g African American men with BMI at least 35 (P for trend = .03).

132 azard ratio [HR], 1.49 [95% CI, 0.95, 2.34]; P for trend = .03).

133 with the lowest was 0.87 (95% CI, 0.79-0.96; P for trend = .03).

134 0.27%, 0.16%, 0.2%, and 0.11%, respectively (P for trend = .03).

135 <25 vs >/=35: HR, 2.22 [95% CI, 1.17-4.21]; P for trend = .05).

136 ottom quintiles was 1.50 (95% CI, 0.84-2.68; P for trend = .05).

137 ased marginally with increasing alcohol use (P for trend = .062).

138 allelic hazard ratio (HR)=1.81 (1.49-2.19); P for trend=1.90 x 10(-9)).

139 s quintile 1 MVRR = 0.82; 95% CI, 0.67-1.01; P for trend = .11; 486 case patients with IOP <22 mm Hg:

140 s quintile 1 MVRR = 0.71; 95% CI, 0.53-0.96; P for trend = .12).

141 tality risk (HR, 1.25; 95% CI, 0.93 to 1.67; P for trend = .126).

142 porting use of any supplements in 2011-2012 (P for trend = .19).

143 2 rs10490924 and Complement Factor H Y402H (P for trend = 4.2x10(-7)).

144 ng either definition, over the study period (P for trend = .46).

145 s quintile 1 MVRR = 0.85; 95% CI, 0.68-1.06; P for trend = .50).

146 (7.8% [1.1%] in 2001 vs 6.3% [1.7%] in 2012, P for trend = .54).

147 score were decreased and increased (log-rank ps for trend: 6 x 10E-4 and 9 x 10E-45), respectively.

148 valence = 11%) versus <2.0 (prevalence = 9%; p for trend across 5 groups = 2 x 10E-35).

149 o, 1.56; 95% confidence interval, 1.17-2.08; P for trend across quartiles=0.003).

150 for trend <0.001, P for nonlinearity <0.001; P for trend differences >0.05) risks.

151 herapy (MHT; HR, 1.16; 95% CI, 1.03 to 1.30; P for trend for duration = .001).

152 11.2% in men and from 5.7% to 8.7% in women (P for trends for both groups < 0.001).

153 ancer and genomic DNA methylation level (all p for trend >0.05).

154 994, 1991-1992, and 1989-1990, respectively (P for trend < .0001).

155 ISU]; P for trend < .001 [for percentages], P for trend < .001 [for levels]).

156 s (24% +/- 20%; 3 ISU [95% CI, 2.4-3.4 ISU]; P for trend < .001 [for percentages], P for trend < .001

157 % vs 16.7% and 52.9% vs 14.2%, respectively; P for trend < .001 for both scores).

158 prescriptions: HR = 3.65, 95% CI, 2.64-5.05; P for trend < .001) and possible CKD (0 prescriptions: H

159 o 19% (difference, 14% [95% CI, 12% to 17%], P for trend < .001) and use of fish oil supplements incr

160 of patients with VT/VF OHCA (46.9% to 60.1%, P for trend < .001) in those with STE (59.2% to 74.3%, P

161 prescriptions: HR = 2.54, 95% CI, 1.81-3.57; P for trend < .001) or possible CKD (1-2 prescriptions:

162 d < .001) in those with STE (59.2% to 74.3%, P for trend < .001) or without STE (43.3% to 56.8%, P fo

163 12% (difference, 11% [95% CI, 9.1% to 12%], P for trend < .001) over the study period, whereas use o

164 s quintile 1 MVRR = 0.56; 95% CI, 0.40-0.79; P for trend < .001) than for POAG with peripheral VF los

165 sk of death increased with increasing stage (P for trend < .001), and patients with stage III disease

166 n 2012 (odds ratio, 2.47; 95% CI, 2.25-2.71; P for trend < .001), and PCI increased from 9.5% in 2000

167 prescriptions, HR = 2.48, 95% CI, 1.80-3.42; P for trend < .001), as was use of anticonvulsants (defi

168 prescriptions: HR = 2.88, 95% CI, 2.17-3.81; P for trend < .001), whereas use of anticonvulsants, ant

169 rend < .001) or without STE (43.3% to 56.8%, P for trend < .001).

170 with paracentral VF loss (95% CI, 0.29-0.96; P for trend < .001).

171 arotenoid index was 0.65 (95% CI, 0.53-0.80; P for trend < .001).

172 extreme quintiles = 0.59; 95% CI, 0.48-0.73; P for trend < .001).

173 Is improved from 11% in 2003 to 93% in 2013 (P for trend < .001).

174 prescriptions: HR = 1.97, 95% CI, 1.34-2.90; P for trend < .001).

175 eeks, 34%; 25 weeks, 27%; and 26 weeks, 17%; P for trend < .001).

176 o <5; 1.47; 95% CI, 1.16-1.85 for NLR >/= 5; P for trend < .001).

177 (difference, -5.7% [95% CI, -8.6% to -2.7%], P for trend < .001).

178 n 2012 (odds ratio, 4.80; 95% CI, 4.21-5.66; P for trend < .001).

179 reased in patients with STE (53.7% to 87.2%, P for trend < .001, and 29.7% to 77.3%, P for trend < .0

180 vely) and those without STE (19.3% to 33.9%, P for trend < .001, and 3.5% to 11.8%, P for trend < .00

181 29.5% in adults without a history of cancer (P for trend < .001, both groups).

182 .2%, P for trend < .001, and 29.7% to 77.3%, P for trend < .001, respectively) and those without STE

183 3.9%, P for trend < .001, and 3.5% to 11.8%, P for trend < .001, respectively).

184 prescriptions, HR = 2.30, 95% CI, 1.53-3.44; P for trend < .001; possible CKD, 1-2 prescriptions: HR

185 e were 2.2, 3.3, 4.0, and 9.9, respectively (P for trend < 0.0001) after adjustment for other risk fa

186 0 (from 3.3% to 2.3%, relative change 30.5%; p for trend < 0.0001) but not for men (from 2% to 1.8%,

187 A was positively associated with ALT levels (p for trend < 0.0001), indicating possible liver toxicit

188 eased risk of rosacea among current smokers (P for trend < 0.0001).

189 = 1.10, 95% confidence interval: 1.06, 1.15; P for trend < 0.001) and acetaminophen use (for >6 years

190 days) to 12.7 days (CI, 11.2 to 14.3 days) (P for trend < 0.001) and across levels of long-form s

191 from 1.0 (referent) to 2.5 (CI, 1.9 to 3.3) (P for trend < 0.001) and across levels of long-form s

192 ease mortality (HR, 0.78 [CI, 0.68 to 0.90]; P for trend < 0.001) and cerebrovascular disease mortali

193 9 to 2.63]; and HR, 2.63 [CI, 1.60 to 4.30]; P for trend < 0.001) and longer sedentary bout duration

194 tality for men (HR, 0.41 [CI, 0.32 to 0.54]; P for trend < 0.001) and women (HR, 0.60 [CI, 0.46 to 0.

195 s prevalence increased in men (6.2% to 9.6%; P for trend < 0.001) but not women (7.6% to 7.5%; P for

196 e 1.57 (95% confidence interval: 1.22, 2.02; P for trend < 0.001) for dietary LI and 1.30 (95% confid

197 dlife was related to 34% (95% CI, 9% to 66%; P for trend < 0.001) greater odds of healthy versus usua

198 = 1.09, 95% confidence interval: 1.04, 1.14; P for trend < 0.001) were associated with higher risks o

199 0 to 1.85]; and HR, 1.96 [CI, 1.31 to 2.93]; P for trend < 0.001) were both associated with a higher

200 erval (CI): 1.14, 1.33) for red meat intake (P for trend < 0.001), 1.15 (95% CI: 1.06, 1.24) for poul

201 independently associated with BMI in women (P for trend < 0.001), but not in men.

202 4 cups per day: HR, 0.82 [CI, 0.78 to 0.87]; P for trend < 0.001).

203 ed with greater late-life cognitive decline (P for trend < 0.001).

204 d in the demographically adjusted model (all P for trend < 0.001).

205 73 for total omega3-PUFAs (CI, 0.61 to 0.86; P for trend < 0.001).

206 ty was also associated with higher CVD risk (p for trend < 0.001).

207 se trends were observed among nonsilicotics (P for trend < 0.001).

208 in both men (P for trend = 0.02) and women (P for trend < 0.001).

209 001) and women (HR, 0.60 [CI, 0.46 to 0.78]; P for trend < 0.001).

210 days) to 11.9 days (CI, 10.8 to 12.9 days) (P for trend < 0.001).

211 from 1.0 (referent) to 2.5 (CI, 1.6 to 3.7) (P for trend < 0.001).

212 ality (men: HR, 0.88 [95% CI, 0.82 to 0.95]; P for trend < 0.001; women: HR, 0.93 [CI, 0.87 to 0.98];

213 = 0.60, 95% confidence interval: 0.41, 0.89; P for trend < 0.01) and to horse farming (>/=20 years: h

214 .27 kg/year less weight (95% CI: 0.12, 0.41; P for trend < 0.01) during the 10-year follow-up.

215 nificantly increased odds ratios of obesity (P for trend < 0.01) in women.

216 , grains, egg) and most other allergy diets (P for trend < 0.01).

217 intile) = 2.75; 95% CI, 1.47-5.15; p < 0.01; p for trend < 0.01).

218 st quartile (mean, 27.7, 95% CI: 27.0, 28.4; P for trend < 0.01).

219 octane sulfonate and perfluorooctanoic acid (P for trend < 0.01).

220 evels and TSB levels at 48 hours postpartum (P for trend < 0.01).

221 d with better cognitive function in midlife (p for trend < 0.01, for all).

222 e mortality (HR = 1.27, 95% CI: 1.07, 1.51) (P for trend < 0.02 for these outcomes) but not for coron

223 with evidence of dose-response relationship (P for trend < 0.05).

224 ncluded adjustment for IGF-1 concentrations (P for trend < 0.05).

225 e patients (15.8% in 2000 and 23.2% in 2014; P for trend <.001 for both), with greater survival impro

226 OR, 0.38 [95% CI, 0.29-0.49]), respectively (P for trend <.001 in both comparisons).

227 (1.36-3.51) for Q1 (P = .001) (worst scores; P for trend <.001) after adjustment for sex and educatio

228 nts, OR, 2.13 [95% CI, 1.66-2.75], P < .001; P for trend <.001).

229 from 2001 through 2012 ($29 507 vs $79 607, P for trend <.001).

230 011-2012 (difference, 8% [95% CI, 3.8%-12%]; P for trend <.001).

231 -2012 (difference, 6.6% [95% CI, 4.4%-8.2%]; P for trend <.001).

232 76-.83) for counties with >/=31% vaccinated (P for trend <.001).

233 th an increased risk of cataract extraction (P for trend <.001).

234 the risk for cataract extraction with time (P for trend <.001).

235 P = .004) and intensity of current smoking (P for trend <.001).

236 ll-cause death (HR, 0.70; 95% CI, 0.54-0.91; P for trend <.001).

237 cantly from 2001 through 2012 (3177 vs 1345, P for trend <.001).

238 equency of MACCE declined from 3.1% to 2.6% (P for trend <.001; adjusted odds ratio [aOR], 0.95; 95%

239 stroke from 0.52% in 2004 to 0.77% in 2013 (P for trend <.001; aOR 1.79; CI 1.73-1.86).

240 clinical categories of 25-hydroxyvitamin D (p for trend </= 2 x 10(-3)).

241 quartile versus the lowest quartile of fT4; P for trend </=0.001 across quartiles).

242 ries were 1.0, 1.56, and 3.71, respectively (P for trend <0.0001 for each).

243 es of CV death (2.66 [95% CI: 1.48 to 4.81]; p for trend <0.0001), myocardial infarction (1.39 [95% C

244 mg, prasugrel, and ticagrelor, respectively; P for trend <0.0001).

245 n 20 years and gradually increased with age (p for trend <0.0001).

246 95% confidence interval (CI): 1.21 to 1.94]; p for trend <0.0001).

247 mpared with those least socially integrated (P for trend <0.0001).

248 8), and stroke (1.60 [95% CI: 1.22 to 2.11]; p for trend <0.0001).

249 eneous GGNs 36.4%; part-solid nodules 85.5%, P for trend <0.0001).

250 re covariables (1.53 [95% CI: 1.20 to 1.95]; p for trend <0.0001); the association remained in separa

251 rtality, and HCC in a dose-dependent manner (P for trend <0.0001, <0.0001, and 0.009, respectively).

252 chemic stroke and the individual components (P for trend <0.001 for all).

253 R, 2.61; 95% confidence interval, 1.81-3.78; P for trend <0.001) and BNP (aHR, 1.45; 95% confidence i

254 0-15.5]% versus UACR Q4 = 14.6 [14.3-14.9]%, P for trend <0.001) and increased E/e' ratio (Q1 = 25.3

255 0.80 (95% confidence interval: 0.72 to 0.89; p for trend <0.001), respectively.

256 led during the study period (21.4% to 59.3%; P for trend <0.001), thereby decreasing time from emerge

257 eclined from 61.0% in 2002 to 49.0% in 2014 (P for trend <0.001), while mortality for males declined

258 ars of age (aRR: 1.27; 95% CI: 1.19 to 1.36; p for trend <0.001).

259 interval, 1.07-1.61) for hs-cTnT >/=14 ng/L (P for trend <0.001).

260 R, 1.94; 95% confidence interval, 1.41-2.68; P for trend <0.001).

261 ], 2.19; 95% confidence interval, 1.56-3.06; P for trend <0.001).

262 o 4 versus no age-related signs at baseline (P for trend <0.001).

263 eclined from 48.6% in 2002 to 32.2% in 2014 (P for trend <0.001).

264 coronary heart disease and stroke combined (p for trend <0.001).

265 to 90 minutes 25.2%, and >90 minutes 39.6% (P for trend <0.001).

266 artiles of baseline NT-proBNP, respectively (P for trend <0.001).

267 to pulseless electrical activity over time (P for trend <0.001).

268 d with increasing age when first overweight (P for trend <0.001).

269 , -7.5, -9.7, and -20.8 mm Hg, respectively (p for trend <0.001).

270 95% confidence interval [CI]: 1.85 to 2.33; p for trend <0.001).

271 ncreasing body surface area affected by PsO (P for trend <0.001).

272 red with 1.6% in patients with a score </=9 (P for trend <0.001).

273 ars of age (aRR: 2.67; 95% CI: 2.37 to 3.01; p for trend <0.001); SNF admission risk was highest in t

274 ry heart disease (P for heterogeneity=0.001, P for trend <0.001, P for nonlinearity <0.001) and strok

275 sk was identified (P for heterogeneity=0.09, P for trend <0.001, P for nonlinearity <0.001).

276 0.001) and stroke (P for heterogeneity=0.07, P for trend <0.001, P for nonlinearity <0.001; P for tre

277 Warfarin use decreased from 52.4% to 34.8% (p for trend <0.01), and DOAC use increased from 0% to 25

278 1), and DOAC use increased from 0% to 25.8% (p for trend <0.01).

279 m 52.4% to 60.7% among eligible AF patients (p for trend <0.01).

280 from the highest to the lowest apoE tertile (p for trends < 1 x 10(-6) ).

281 4.5% to 3.3%, a relative decline of -27.4%, (p-for-trend <0.001), but patients 18 to 44 years of age

282 463 hospital stays/100,000 persons, (-26.9%, p-for-trend <0.001).

283 9), 0.80 (0.74, 0.86) and 0.80 (0.74, 0.87) (p for trend = <0.001) for 0, 1-60, 61-150, 151-300, and

284 ), 0.83 (0.69, 1.00), and 0.70 (0.57, 0.85) (p for trend = <0.001) for cycling 0, 1-60, 61-150, and >

285 atic model assessment of insulin resistance (P for trend<0.001) and 2-hour glucose levels (P for tren

286 he GRS relating to 0.028 mm greater CCA IMT, p for trend<0.001) than those with SBP<120 mmHg and DBP<

287 from 14.3% in 2005 to 2006 to 20.8% in 2012 (P for trend<0.001), and in-hospital survival (P for tren

288 able initial rhythm (N=2823; 29.1% to 41.4%; P for trend<0.001).

289 creasing usage over the time period studied (P for trend<0.001).

290 creased with increasing months of lactation (P for trend<0.01), whereas among obese women (BMI>/=30),

291 Bleeding increased across risk groups (P for trend<0.01); however, net clinical outcome was inc

292 0.95 (0.73-1.22), and 0.70 (0.53-0.93), and P for trend<0.01.

293 1.8%; and for scores of 13-15, it was 72.1% (P for trend, <.0001).

294 62 (95% CI, 2.17-3.08), an increase of 205% (P for trend, <.001).

295 05 (95% CI, 0.87-1.23), an increase of 950% (P for trend, <.001).

296 7 (95% CI, 9.48-10.85), an increase of 176% (P for trend, <.001).

297 71 (95% CI, 3.44-3.98), an increase of 165% (P for trend, <.001).

298 51 (95% CI, 2.21-2.80), an increase of 161% (P for trend, <.001); poisonings involving methadone incr

299 ed with the severity of cytological results (P for trend, <0.05).

300 to unnatural cause were analyzed separately (P for trend or difference < 0.0001), and for women with